Drugs / 64Cu-DOTA-daratumumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03311828 | Feb 2018 → Jan 2020 | AA amyloidosis, plasma cell myeloma | City of Hope Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-DOTA-daratumumab | “copper 64Cu-DOTA-daratumumab positron emission tomography” NCT03311828 ↗ |
| Known as | 64Cu-daratumumab | “tracing MM dissemination using a CD38-directed human antibody, daratumumab, that is radioconjugated with 64Cu via the chelator DOTA (64Cu-daratumumab)” PMID 33095874 ↗ Oct 2020 |
| Modality | Diagnostic / imaging agent | “copper 64Cu-DOTA-daratumumab positron emission tomography” NCT03311828 ↗ |
| Route | Intravenous | “within 6 hours, patients receive copper 64Cu-DOTA-daratumumab IV on day 0” NCT03311828 ↗ |